17-alpha-hydroxyprogesterone has been researched along with Adenocarcinoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Gislefoss, RE; Lagergren, J; Langseth, H; Mattsson, F; Ness-Jensen, E; Rabbani, S; Xie, SH | 1 |
| HENRIKSEN, E; VARGA, A | 2 |
| Arduino, S; Bellino, R; Febo, G; Lanza, A; Leo, L; Tessarolo, M; Wierdis, T | 1 |
| Fujimoto, J; Hori, M; Ichigo, S; Tamaya, T | 1 |
| Georgitis, WJ | 1 |
| Caldarola, B; D'Addato, F; Ferraris, G; Lanza, A; Proserpio, D; Raspollini, M; Re, A; Rocca, G; Vigezzi, P; Zardo, L | 1 |
1 review(s) available for 17-alpha-hydroxyprogesterone and Adenocarcinoma
| Article | Year |
|---|---|
Circulating Sex Hormone Levels and Risk of Esophageal Adenocarcinoma in a Prospective Study in Men.
Topics: 17-alpha-Hydroxyprogesterone; Adenocarcinoma; Adult; Androstenedione; Case-Control Studies; Dehydroepiandrosterone Sulfate; Esophageal Neoplasms; Estradiol; Follicle Stimulating Hormone; Gonadal Steroid Hormones; Gonadotropins, Pituitary; Humans; Logistic Models; Luteinizing Hormone; Male; Middle Aged; Norway; Progesterone; Prolactin; Prospective Studies; Risk Factors; Sex Hormone-Binding Globulin; Testosterone | 2020 |
6 other study(ies) available for 17-alpha-hydroxyprogesterone and Adenocarcinoma
| Article | Year |
|---|---|
Clinical and histopathologic evaluation of the effect of 17-alpha-hydroxyprogesterone-17-n-caproate on endometral carcinoma.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Adenocarcinoma; Adenocarcinoma, Papillary; Caproates; Female; Humans; Hydroxyprogesterones; Progesterone; Uterine Neoplasms | 1961 |
EFFECT OF 17-ALPHA-HYDROXYPROGESTERONE 17-N-CAPROATE ON VARIOUS PELVIC MALIGNANCIES.
Topics: 17-alpha-Hydroxyprogesterone; Adenocarcinoma; Antineoplastic Agents; Caproates; Carcinoma, Squamous Cell; Choriocarcinoma; Female; Humans; Hydroxyprogesterones; Mesenchymoma; Neoplasms; Ovarian Neoplasms; Pelvic Neoplasms; Pregnancy; Sarcoma; Uterine Cervical Neoplasms; Uterine Neoplasms | 1964 |
Endometrial carcinoma in women 45 years of age or younger.
Topics: 17-alpha-Hydroxyprogesterone; Adenocarcinoma; Adult; Age Distribution; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone; Middle Aged; Neoplasm Staging; Progesterone Congeners; Prognosis; Radiotherapy, Adjuvant; Survival Rate | 1996 |
Sex steroids regulate the expression of plasminogen activator inhibitor-1 (PAI-1) and its mRNA in uterine endometrial cancer cell line Ishikawa.
Topics: 17-alpha-Hydroxyprogesterone; Adenocarcinoma; DNA, Neoplasm; Endometrial Neoplasms; Estradiol; Female; Gene Expression Regulation, Neoplastic; Gonadal Steroid Hormones; Humans; Medroxyprogesterone Acetate; Neoplasm Proteins; Neovascularization, Pathologic; Plasminogen Activator Inhibitor 1; Polymerase Chain Reaction; Progesterone; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator | 1996 |
Clinically silent congenital adrenal hyperplasia masquerading as ectopic adrenocorticotropic hormone syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adenocarcinoma; Adrenal Hyperplasia, Congenital; Adrenocorticotropic Hormone; Carcinoma, Squamous Cell; Cortodoxone; Humans; Hydroxyprogesterones; Lung Neoplasms; Male; Middle Aged; Steroid Hydroxylases; Syndrome | 1986 |
Hormonal and surgical treatment of endometrial adenocarcinoma: actuarial survival.
Topics: 17-alpha-Hydroxyprogesterone; Adenocarcinoma; Combined Modality Therapy; Female; Humans; Hydroxyprogesterones; Prognosis; Uterine Neoplasms | 1988 |